Novavax (NVAX) Receivables - Other (2016 - 2025)
Historic Receivables - Other for Novavax (NVAX) over the last 12 years, with Q3 2025 value amounting to $5.2 million.
- Novavax's Receivables - Other fell 1612.9% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 1612.9%. This contributed to the annual value of $5.4 million for FY2024, which is 5000.0% down from last year.
- Novavax's Receivables - Other amounted to $5.2 million in Q3 2025, which was down 1612.9% from $5.3 million recorded in Q2 2025.
- Novavax's Receivables - Other's 5-year high stood at $68.0 million during Q3 2022, with a 5-year trough of $200000.0 in Q1 2024.
- Its 5-year average for Receivables - Other is $26.9 million, with a median of $28.6 million in 2022.
- Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 9953.16% in 2024, then soared by 295000.0% in 2025.
- Novavax's Receivables - Other (Quarter) stood at $35.3 million in 2021, then decreased by 18.98% to $28.6 million in 2022, then crashed by 62.24% to $10.8 million in 2023, then tumbled by 50.0% to $5.4 million in 2024, then fell by 3.7% to $5.2 million in 2025.
- Its Receivables - Other was $5.2 million in Q3 2025, compared to $5.3 million in Q2 2025 and $6.1 million in Q1 2025.